Physician profile
Sherry Farzan
NPI 1902082431
$4,976.65
in general payments reported to CMS, 2019-2025
17 companies · $38.11 in 2025
The $38.11 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $72.24 · 2021: $1,401 · 2022: $1,524 · 2023: $1,599 · 2024: $235 · 2025: $38.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,464 · Food and Beverage: $384 · Gift: $24.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,464.00 |
| Food and Beverage | $384.28 |
| Gift | $24.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,295.68 | 2020-2023 | |
| Teva Pharmaceuticals USA, INC. | $135.00 | 2023 | Austedo |
| Amgen INC. | $125.00 | 2024 | Tepezza |
| Intuity Medical INC | $111.11 | 2022 | |
| Abbvie INC. | $110.39 | 2024 | |
| Glaxosmithkline, LLC. | $42.77 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $38.11 | 2025 | |
| Genentech USA, INC. | $36.33 | 2019-2020 | |
| Shire North American Group INC | $17.26 | 2019 | |
| Csl Behring | $17.16 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.86 | 2020 | |
| Grifols USA, LLC | $15.96 | 2019 | |
| Alk-Abello, INC | $15.02 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Farzan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.